Levosimendan Facilitates Weaning From Cardiopulmonary Bypass in Patients Undergoing Coronary Artery Bypass Grafting With Impaired Left Ventricular Function

Annals of Thoracic Surgery

Volumn 87, Issue 2, 2009, Pages 448-454

  Eriksson, Heidi I ^a   Jalonen, Jouko R ^b   Heikkinen, Leo O ^a   Kivikko, Matti ^c   Laine, Mika ^a   Leino, Kari A ^b   Kuitunen, Anne H ^a   Kuttila, Kari T ^b   Peräkylä, Tarja K ^a   Sarapohja, Toni ^c   Suojaranta Ylinen, Raili T ^a   Valtonen, Mika ^b   Salmenperä, Markku T ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c ORION CORPORATION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; LACTIC ACID; LEVOSIMENDAN; PLACEBO;

ADULT; AGED; AORTA BALLOON; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; FLUID BALANCE; HEART HEMODYNAMICS; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; VENOUS OXYGEN TENSION;

AGED; ANALYSIS OF VARIANCE; CARDIOPULMONARY BYPASS; CONFIDENCE INTERVALS; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY STENOSIS; DOUBLE-BLIND METHOD; EDUCATION, MEDICAL, CONTINUING; FEMALE; HEMODYNAMICS; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MONITORING, INTRAOPERATIVE; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PYRIDAZINES; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 58249132859     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2008.10.029     Document Type: Article

References (33)

1. Lewis K.P., Appadurai I.R., Pierce E.T., Halpern E.F., and Bode Jr. R.H. Prophylactic amrinone for weaning from cardiopulmonary bypass. Anaesthesia 55 (2000) 627-633
2. Butterworth IV J.F., Royster R.L., Prielipp R.C., Lawless S.T., and Wallenhaupt S.L. Amrinone in cardiac surgical patients with left-ventricular dysfunction. A prospective, randomized placebo-controlled trial. Chest 104 (1993) 1660-1667
3. Lobato E.B., Florete Jr. O., and Bingham H.L. A single dose of milrinone facilitates separation from cardiopulmonary bypass in patients with pre-existing left ventricular dysfunction. Br J Anaesth 81 (1998) 782-784
4. Menzner Jr. R.M., Mehmet C.O., Sladen R.N., et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery. The NAPA Trial. J Am Coll Cardiol 49 (2007) 716-726
5. Wu X., and Bers D.M. Sarcoplasmic reticulum and nuclear envelope are one highly interconnected Ca2+ store throughout cardiac myocyte. Circ Res 99 (2006) 283-291
6. Haikala H., Nissinen E., Etemadzadeh E., Levijoki J., and Linden I.B. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 25 (1995) 794-801
7. Nijhawan N., Nicolosi A.C., Montgomery M.W., Aggarwal A., Pagel P.S., and Warltier D.C. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 34 (1999) 219-228
8. Lilleberg J., Nieminen M.S., Akkila J., et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 19 (1998) 660-668
9. Pataricza J., Krassoi I., Hohn J., Kun A., and Papp J.G. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 17 (2003) 115-121
10. Rump A.F., Acar D., Rosen R., and Klaus W. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol 74 (1994) 244-248
11. Kersten J.R., Montgomery M.W., Pagel P.S., and Warltier D.C. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 90 (2000) 5-11
12. Givertz M.M., Andreou C., Conrad C.H., and Colucci W.S. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships. Circulation 115 (2007) 1218-1224
13. Jörgensen K., Bech-Hanssen O., Houltz E., and Ricksten S.E. Effects of levosimendan on left ventricular relaxation and early filling at maintained preload and afterload conditions after aortic valve replacement for aortic stenosis. Circulation 117 (2008) 1075-1081
14. Kloner R.A., Przyklenk K., and Kay G.L. Clinical evidence for stunned myocardium after coronary artery bypass surgery. J Card Surg 9 (1994) 397-402
15. Stamm C., Friehs I., Cowan D.B., et al. Dopamine treatment of postischemic contractile dysfunction rapidly induces calcium-dependent pro-apoptotic signaling. Circulation 106 (2002) 290-298
16. Jamali I.N., Kersten J.R., Pagel P.S., Hettrick D.A., and Warltier D.C. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 85 (1997) 23-29
17. Du Toit E.F., Muller C.A., McCarthy J., and Opie L.H. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 290 (1999) 505-514
18. Du Toit E.F., Genis A., Opie L.H., Pollesello P., and Lochner A. A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol 154 (2008) 41-50
19. Tritapepe L., De Santis V., Vitale D., et al. Preconditioning effects of levosimendan in coronary artery bypass grafting - a pilot study. Br J Anaesth 96 (2006) 694-700
20. Stowe D.F., and Kevin L.G. Cardiac preconditioning by volatile anesthetic agents: a defining role for altered mitochondrial bioenergetics. Antioxid Redox Signal 6 (2004) 439-448
21. Raja S.G., and Rayen B.S. Levosimendan in cardiac surgery: current best available evidence. Ann Thorac Surg 81 (2006) 1536-1546
22. Lehmann A., Lang J., Boldt J., Isgro F., and Kiessling A.H. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit 10 (2004) MT89-MT93
23. Iriz E., Erer D., Unal Y., Zor H., Ozkose Z., and Ozdogan M.E. Successful use of levosimendan in a patient during cardiopulmonary bypass. J Card Surg 22 (2007) 153-156
24. Labriola C., Siro-Brigiani M., Carrata F., Santangelo E., and Amantea B. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther 42 (2004) 204-211
25. Siirilä-Waris K., Suojaranta-Ylinen R., and Harjola V.P. Levosimendan in cardiac surgery. J Cardiothorac Vasc Anesth 19 (2005) 345-349
26. Petäjä L.M., Sipponen J.T., Hämmäinen P.J., Eriksson H.I., Salmenperä M.T., and Suojaranta-Ylinen R.T. Levosimendan reversing low output syndrome after heart transplantation. Ann Thorac Surg 82 (2006) 1529-1531
27. Samuels L.E., Holmes E.C., and Letwin L. Nesiritide as an adjunctive therapy in adult patients with heart failure undergoing high-risk cardiac surgery. J Thorac Cardiovasc Surg 128 (2004) 627-629
28. De Hert S.G., Lorsomradee S., Cromheecke S., and Van der Linden P.J. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 104 (2007) 766-773
29. Lilleberg J., Laine M., Palkama T., Kivikko M., Pohjanjousi P., and Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 9 (2007) 75-82
30. Pölönen P., Ruokonen E., Hippeläinen M., Pöyhönen M., and Takala J. A prospective, randomized study of goal-oriented hemodynamic therapy in cardiac surgical patients. Anesth Analg 90 (2000) 1052-1059
31. Antila S., Huuskonen H., Nevalainen T., Kanerva H., Vanninen P., and Lehtonen L. Site dependent bioavailability and metabolism of levosimendan in dogs. Eur J Pharm Sci 9 (1999) 85-91
32. Banfor P.N., Preusser L.C., Campbell T.J., et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol 294 (2008) H238-H248
33. Kaheinen P., Pollesello P., Levijoki J., and Haikala H. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol 43 (2004) 555-561